MedTrace Logo

Effect of Anti-IgE in Non-Allergic Asthma

NCT00162773 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2017-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.

Conditions

Interventions

DRUG

omalizumab

150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.

OTHER

Placebo

150-375 milligrams depending on body weight and serum IgE.

Sponsors & Collaborators

Principal Investigators

  • Peter S Creticos, M.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162773 on ClinicalTrials.gov